RDMD raises $14M for rare disease real-world evidence generation
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform
System1 Biosciences' platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
Neurology startup Magnolia Neurosciences raises $31M in Series A round
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.
Therachon raises $60 million in mezzanine financing for rare disease drugs
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.